30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations

30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.

We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London.